{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Bardoxolone",
  "nciThesaurus": {
    "casRegistry": "218600-44-3",
    "chebiId": "",
    "chemicalFormula": "C31H41NO4",
    "definition": "A synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3; Bcl-3 is an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression.",
    "fdaUniiCode": "7HT68L8941",
    "identifier": "C48382",
    "preferredName": "Bardoxolone",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1323",
      "C29574"
    ],
    "synonyms": [
      "2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid",
      "2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic Acid",
      "BARDOXOLONE",
      "Bardoxolone",
      "CDDO",
      "Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-",
      "RTA 401"
    ]
  }
}